Huayuan Zhiyin, an AI virtual cell company, has secured a seed funding round of tens of millions of RMB, led by Shuimu Ventures. The company utilizes its proprietary Wise-Perturb model to predict drug efficacy and toxicity in humans, aiming to reduce the high failure rates in new drug development. Their approach integrates multi-omics data from single cells to create more accurate predictions than traditional methods, and they are collaborating with top hospitals and pharmaceutical companies for validation and service delivery. AI
IMPACT This funding could accelerate the development of AI-driven drug discovery tools, potentially reducing R&D costs and timelines for new pharmaceuticals.
RANK_REASON Significant funding round for an AI company in the drug discovery space. [lever_c_demoted from significant: ic=1 ai=0.7]
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
